Cellectar Biosciences Inc. (CLRB) is priced at $1.51 after the most recent trading session. At the very opening of the session, the stock price was $1.26 and reached a high price of $1.77, prior to closing the session it reached the value of $1.26. The stock touched a low price of $1.18.
Recently in News on November 9, 2020, Cellectar Reports Third Quarter 2020 Financial Results and Provides a Corporate Update. Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced financial results for the third quarter ended September 30, 2020 and provided a corporate update. You can read further details here
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Cellectar Biosciences Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $3.3300 on 02/18/20, with the lowest value was $1.0100 for the same time period, recorded on 09/04/20.
Cellectar Biosciences Inc. (CLRB) full year performance was -31.45%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Cellectar Biosciences Inc. shares are logging -54.50% during the 52-week period from high price, and 50.00% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $1.01 and $3.33.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 6979364 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Cellectar Biosciences Inc. (CLRB) recorded performance in the market was -32.67%, having the revenues showcasing 32.89% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 39.91M, as it employees total of 8 workers.
The Analysts eye on Cellectar Biosciences Inc. (CLRB)
During the last month, 0 analysts gave the Cellectar Biosciences Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 1.2609, with a change in the price was noted +0.0250. In a similar fashion, Cellectar Biosciences Inc. posted a movement of +1.68% for the period of last 100 days, recording 624,447 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for CLRB is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.01.
Technical rundown of Cellectar Biosciences Inc. (CLRB)
Raw Stochastic average of Cellectar Biosciences Inc. in the period of last 50 days is set at 62.50%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 62.50%. In the last 20 days, the company’s Stochastic %K was 78.24% and its Stochastic %D was recorded 78.86%.
Considering, the past performance of Cellectar Biosciences Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -32.67%. Additionally, trading for the stock in the period of the last six months notably improved by 47.09%, alongside a downfall of -31.45% for the period of the last 12 months. The shares increased approximately by 24.18% in the 7-day charts and went down by 32.89% in the period of the last 30 days. Common stock shares were driven by 32.89% during last recorded quarter.